Aims to Characterize Substrate Recognition Mechanism and Screen for Potential

Drug Compounds that Inhibit Amyloid Build-up

Montara, California, April 22, 2009 – Molecular Sensing, Inc. (MSI) today announced that it has entered into a Life Science Early Access Program (LEAP) research agreement with VIB to use MSI’s proprietary Back-Scattering Interferometry (BSI) technology to study ligand binding to the membrane-bound ã-secretase complex, an alternative drug target in Alzheimer’s disease (AD). The aim of the project is the characterization of the substrate recognition mechanism of the ã-secretase complex and to screen for potential drug compounds that inhibit amyloid build-up. Financial details were not disclosed.

Dr. Bart de Strooper of the VIB Department of Molecular and Developmental Genetics at the K.U.Leuven is a leading international expert in Alzheimer’s research and was accorded the $200,000 MetLife prize in 2008 for his pioneering research. “Elucidation of the structure-function relationship of the active ã-secretase complex is important for understanding the basic biology and pathogenesis of AD. Development of APP-selective ã-secretase inhibitors is one of the major directions in AD therapeutics”, says Dr. de Strooper.

“BSI is a breakthrough in molecular interaction assay technology, in particular, characterizing ligand binding to integral, membrane-bound proteins” said Scot Weinberger, MSI’s President and Chief Executive Officer. “We are pleased to work with Dr. de Strooper and VIB to enhance their efforts and progress towards understanding the mechanisms of AD and elucidating new and improved therapeutics for its treatment.”